BRAIN Biotech AGHAM:BNN 65 Dividend Yield % is 0.00% as of Jun. 26, 2026. GuruFocus rates HAM:BNN with a GF Score™ of 65/100 and a GF Value™ of €2.51 (Modestly Overvalued). The stock has 2 warning signs investors should review. Among 1,067 Chemicals companies, BRAIN Biotech AG ranks worse than 93720.62% on this metric.
As of today (2026-06-26), the Trailing Annual Dividend Yield of BRAIN Biotech AG is 0.00%.
The historical rank and industry rank for BRAIN Biotech AG's Dividend Yield % or its related term are showing as below:
HAM:BNN's Dividend Yield % is not ranked *
in the Chemicals industry.
Industry Median: 1.48 * Ranked among companies with meaningful Dividend Yield % only.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.
BRAIN Biotech AG (HAM:BNN) Dividend Yield % Explanation
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
The historical data trend for BRAIN Biotech AG's Dividend Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HAM:BNN vs LIN, SHW, ECL: Dividend Yield % Comparison
For the Specialty Chemicals subindustry, BRAIN Biotech AG's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BRAIN Biotech AG Dividend Yield % vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, BRAIN Biotech AG's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where BRAIN Biotech AG's Dividend Yield % falls into.
BRAIN Biotech AG (HAM:BNN) has a Dividend Yield % of 0.00% as of Jun. 26, 2026. Dividend yield is the ratio of company dividends to the share price. View historical data on BRAIN Biotech AG and its competitors. According to the industry distribution chart, BRAIN Biotech AG ranks #999999 out of 1067 companies in the Chemicals industry.
Is BRAIN Biotech AG's Dividend Yield % too high?
BRAIN Biotech AG's current Dividend Yield % is 0.00%. Based on the distribution chart, BRAIN Biotech AG ranks #999999 out of 1067 companies in the Chemicals industry, which is in the bottom quartile relative to peers. Overall, BRAIN Biotech AG has a GF Score™ of 65/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does BRAIN Biotech AG's Dividend Yield % compare to LIN and SHW?
According to the Chemicals industry distribution chart, BRAIN Biotech AG ranks #999999 out of 1067 companies for Dividend Yield %. This places BRAIN Biotech AG in the lower half of its industry. The industry median Dividend Yield % is 1.48. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Yield % for a Chemicals company?
The median Dividend Yield % among Chemicals companies is 1.48, based on 1,067 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Yield % mean?
A high Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Dividend yield is the ratio of company dividends to the share price. View historical data on BRAIN Biotech AG and its competitors. For the Chemicals industry, the median Dividend Yield % is 1.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BRAIN Biotech AG's current Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BRAIN Biotech AG stock overvalued right now?
Based on GuruFocus' analysis, BRAIN Biotech AG (HAM:BNN) is currently considered Modestly Overvalued. The stock's GF Value™ is €2.51, compared to a current price of €2.82 — trading 12.4% above its estimated fair value. The current Dividend Yield % is 0.00%. BRAIN Biotech AG's overall GF Score™ is 65/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Yield % calculated?
Dividend Yield % is calculated from a company's financial statements. For BRAIN Biotech AG (HAM:BNN), the current Dividend Yield % is 0.00% as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BRAIN Biotech AG (HAM:BNN) Overvalued in 2026?
Based on GuruFocus' analysis, BRAIN Biotech AG stock appears to be overvalued.
The current stock price of €2.82 is trading 12.4% above its estimated GF Value™ of €2.51.
GuruFocus considers BRAIN Biotech AG to be Modestly Overvalued.
Key valuation signals for HAM:BNN:
Dividend Yield %: 0.00%
GF Value™: €2.51 vs. price of €2.82 (12.4% above fair value)
No single metric tells the full story. See the HAM:BNN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BRAIN Biotech AG is an industrial biotechnology specialist focused on enzyme technology, microbial production strains, and bioprocess design to enable bio-based innovations. The Group conducts research, development, and production for client specifications and its own product portfolio, supporting customers in the food and beverage, chemical, and life sciences industries with solutions that enhance productivity, efficiency, and sustainability. Its operations are organized into two segments: BRAIN Biocatalysts, which develops, produces, and distributes specialty enzymes, microorganisms, and ingredients and generates the majority of revenue, and BRAIN BioIncubator, which focuses on development projects. The company operates in Germany and other countries.
65GF Score
Get the complete analysis for HAM:BNN
Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:BNN has been successfully added to your 
